AIM: To investigate the role of insulin-like growth factor binding protein-7 (IGFBP-7) in the activation and transdifferentiation of hepatic stellate cells (HSC) in vitro. METHODS: Rat HSC-T6 cells were cultured in separate dishes and treated with various concentration of transforming growth factor (TGF)-beta(1), IGFBP-7 or anti-IGFBP-7 antibody for 24 h. The supernatant or a cytoplasm suspension was obtained from cultured HSC, followed by transfer of cells to form cell-coated dishes. Immunocytochemistry and Western blotting were used to analyze the expression of IGFBP-7 induced by TGF-beta(1) and the level of fibronectin, collagen I and alpha-smooth muscle actin (SMA). The pro-apoptotic effect of anti-IGFBP-7 antibody was determined by flow cytometry. RESULTS: Immunocytochemistry and Western blotting revealed that the expression of IGFBP-7 in TGF-beta(1) treated HSC was significantly up-regulated compared to that in the control group. In addition, fibronectin, collagen I and alpha-SMA also showed enhanced expression in accordance with the transdifferentiation process in a dose-dependent manner to some extent. Moreover, flow cytometry suggested that anti-IGFBP-7 antibody induced apoptosis of activated HSC, which is responsible for the development of liver fibrosis, and may represent a novel pathway and target for therapeutic intervention. CONCLUSION: IGFBP-7 showed increased expression in activated HSC and played an important role in the activation and transdifferentiation process of HSC. Anti-IGFBP-7 antibody may ameliorate liver fibrogenesis.
AIM: To investigate the role of insulin-like growth factor binding protein-7 (IGFBP-7) in the activation and transdifferentiation of hepatic stellate cells (HSC) in vitro. METHODS:Rat HSC-T6 cells were cultured in separate dishes and treated with various concentration of transforming growth factor (TGF)-beta(1), IGFBP-7 or anti-IGFBP-7 antibody for 24 h. The supernatant or a cytoplasm suspension was obtained from cultured HSC, followed by transfer of cells to form cell-coated dishes. Immunocytochemistry and Western blotting were used to analyze the expression of IGFBP-7 induced by TGF-beta(1) and the level of fibronectin, collagen I and alpha-smooth muscle actin (SMA). The pro-apoptotic effect of anti-IGFBP-7 antibody was determined by flow cytometry. RESULTS: Immunocytochemistry and Western blotting revealed that the expression of IGFBP-7 in TGF-beta(1) treated HSC was significantly up-regulated compared to that in the control group. In addition, fibronectin, collagen I and alpha-SMA also showed enhanced expression in accordance with the transdifferentiation process in a dose-dependent manner to some extent. Moreover, flow cytometry suggested that anti-IGFBP-7 antibody induced apoptosis of activated HSC, which is responsible for the development of liver fibrosis, and may represent a novel pathway and target for therapeutic intervention. CONCLUSION:IGFBP-7 showed increased expression in activated HSC and played an important role in the activation and transdifferentiation process of HSC. Anti-IGFBP-7 antibody may ameliorate liver fibrogenesis.
Authors: K M Kelley; K E Schmidt; L Berg; K Sak; M M Galima; C Gillespie; L Balogh; A Hawayek; J A Reyes; M Jamison Journal: J Endocrinol Date: 2002-10 Impact factor: 4.286
Authors: G Ramadori; T Veit; S Schwögler; H P Dienes; T Knittel; H Rieder; K H Meyer zum Büschenfelde Journal: Virchows Arch B Cell Pathol Incl Mol Pathol Date: 1990
Authors: Loubna Chadli; Britt Sotthewes; Kejie Li; Stefan N Andersen; Ellen Cahir-McFarland; Marc Cheung; Patrick Cullen; Annemarie Dorjée; Jeska K de Vries-Bouwstra; Tom W J Huizinga; David F Fischer; Jeroen DeGroot; Joanne L Viney; Timothy S Zheng; Jamil Aarbiou; Agnes Gardet Journal: Sci Rep Date: 2019-03-14 Impact factor: 4.379
Authors: Lili Niu; Maja Thiele; Philipp E Geyer; Ditlev Nytoft Rasmussen; Henry Emanuel Webel; Alberto Santos; Rajat Gupta; Florian Meier; Maximilian Strauss; Maria Kjaergaard; Katrine Lindvig; Suganya Jacobsen; Simon Rasmussen; Torben Hansen; Aleksander Krag; Matthias Mann Journal: Nat Med Date: 2022-06-02 Impact factor: 87.241
Authors: Takara L Stanley; Lindsay T Fourman; Isabel Zheng; Colin M McClure; Meghan N Feldpausch; Martin Torriani; Kathleen E Corey; Raymond T Chung; Hang Lee; David E Kleiner; Colleen M Hadigan; Steven K Grinspoon Journal: J Clin Endocrinol Metab Date: 2021-01-23 Impact factor: 5.958